Overview


According to FutureWise analysis, the market for oligonucleotide api in 2023 is US$ 2.72 billion, and is expected to reach US$ 6 billion by 2031 at a CAGR of 10.40%.

Oligonucleotides are a novel form of pharmaceutical molecule that can be utilised to treat a variety of diseases. They're little strands of altered DNA, around 20 nucleotides long. The most common process for generating oligonucleotides is to isolate the active pharmaceutical ingredient (API) by lyophilization to make a solid product, which is then dissolved to produce an aqueous formulation. Oligonucleotide active pharmaceutical ingredients (APIs) have previously been utilised in solid solutions (powdered form) and, more recently, in solution form. The oligonucleotide active pharmaceutical ingredient (API) sector is being driven by the widespread usage of oligonucleotide active pharmaceutical ingredients in the treatment of various illnesses. Product development has cleared the way for novel therapeutic procedures in a variety of fields, including ophthalmology, neuromuscular diseases, and vaccine adjuvants. Some of the most significant oligonucleotide classes include micro-RNA, small/short interfering RNA, antisense oligonucleotides, immunostimulatory oligonucleotides, aptamers, and splice-switching oligonucleotides. Some of the characteristics that have boosted the trend of oligonucleotide APIs in solution include solution stability, viscosity, concentration, end-to-end production, and packaging. Because of major breakthroughs made in industry associations regarding CMC (chemistry, manufacturing, and control) methodologies, the market for oligonucleotide APIs is looking brighter. The market for innovative medication classes for chronic obstructive pulmonary disease and asthma is expanding, creating new opportunities. 

FutureWise Market Research has instantiated a report that provides an intricate analysis of Oligonucleotide API Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market. 

According to the research study conducted by FutureWise research analysts, the Oligonucleotide API Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Agilent Technologies, Inc.
  • Bachem Holding AG
  • CordenPharma International
  • Integrated DNA Technologies, Inc. (Danaher Corporation)
  • Eurofins Scientific
  • GE Healthcare
  • Merck KGaA
  • Thermo Fisher Scientific
  • RiBoBio Co.
  • LGC Biosearch Technologies
  • ST Pharm
  • Kaneka Eurogentec S.A.
  • Ajinomoto Co., Inc.
  • Bio-synthesis Inc.
  • STA Pharmaceutical Co., Ltd.
  • BioSpring GmbH

(Note: The list of the major players will be updated with the latest market scenario and trends)

By API Type

  • Antisense Oligonucleotides API
  • Short Interfering RNA (siRNA) API
  • Phosphorodiamidate Morpholino Oligonucleotides (PMO) API
  • MiRNA API
  • Aptamers API
  • CpG Oligonucleotides API
  • Others (ON Conjugates (NP), ShRNA, etc.)

By Marketing Status

  • Marketed
  • Clinical Trials (Clinical Phases)

By End User

  • Contract Manufacturing Organizations (CMOs)
  • Pharmaceutical Companies
  • Biopharmaceutical Companies
  • Contract Development and Manufacturing Organizations (CDMOs)

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa


  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Oligonucleotide API Market By API Type, By Marketing Status, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders

  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study

  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights

  • 4.   Oligonucleotide API Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Oligonucleotide API Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Oligonucleotide API Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Oligonucleotide API Market, By API Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Antisense Oligonucleotides API
        2. Short Interfering RNA (siRNA) API
        3. Phosphorodiamidate Morpholino Oligonucleotides (PMO) API
        4. MiRNA API
        5. Aptamers API
        6. CpG Oligonucleotides API
        7. Others (ON Conjugates (NP), ShRNA, etc.)

  • 8.   Oligonucleotide API Market, By Marketing Status Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Marketed
        2. Clinical Trials (Clinical Phases)

  • 9.   Oligonucleotide API Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Contract Manufacturing Organizations (CMOs)
        2. Pharmaceutical Companies
        3. Biopharmaceutical Companies
        4. Contract Development and Manufacturing Organizations (CDMOs)

  • 10.   North America Oligonucleotide API Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Oligonucleotide API Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Oligonucleotide API Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Oligonucleotide API Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Agilent Technologies, Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Bachem Holding AG
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. CordenPharma International
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Integrated DNA Technologies, Inc. (Danaher Corporation)
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5 . Eurofins Scientific
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. GE Healthcare
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Merck KGaA
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Thermo Fisher Scientific
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. RiBoBio Co.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. LGC Biosearch Technologies
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. ST Pharm
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Kaneka Eurogentec S.A.
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Ajinomoto Co., Inc.
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Bio-synthesis Inc.
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. STA Pharmaceutical Co., Ltd.
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. BioSpring GmbH
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client

FAQ


High manufacturing costs, regulatory complexities, and the need for robust delivery systems for oligonucleotide drugs are market challenges. These are being addressed through technological advancements in synthesis and delivery, strategic collaborations to reduce costs, and ongoing dialogue with regulatory agencies to streamline approval processes.

The market size for Oligonucleotide APIs reflects the demand and growth potential for oligonucleotide-based therapeutics. A larger market size indicates a higher utilization rate of these APIs and an investment opportunity for pharmaceutical and biotech companies in the therapeutics sector, fostering innovation and potentially accelerating the development of new drugs.

Growth in the Oligonucleotide API market share is driven by several factors, including:

  • Advances in biotechnology and life sciences research.
  • Increasing prevalence of genetic and rare diseases.
  • Growing investment in personalized medicine.
  • Technological improvements in oligonucleotide synthesis and modification.

Future trends include:

  • The advent of novel delivery systems to improve oligonucleotide drug effectiveness.
  • Streamlined synthesis processes reducing production costs.
  • Collaborations and mergers in the biotech sector to enhance Research and development capabilities.
  • Increased focus on targeting more complex diseases.

Related Market

Antisense Oligonucleotides Market

Read More

Oligonucleotide Therapeutics Market

Read More

Oligonucleotide Pool Library Market

Read More

Oligonucleotide Synthesis Market

Read More

CNS Specific Antisense Oligonucleotide Market

Read More
Partner

Our Clients